Navigation Links
JACC Publishes Long-Term Safety and Tolerability Data from,Ranolazine Open Label Experience (ROLE) Program

PALO ALTO, Calif., March 14, 2007 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. announced today that the Journal of the of Cardiology (JACC) has published data from the Ranolazine Open Label Experience (ROLE) program, which showed long-term therapy with Ranexa(R) (ranolazine extended-release tablets) to be safe and well tolerated in patients with chronic stable angina who completed one of two phase 3 clinical trials, and enrolled in the ROLE program.

These data also suggest no evidence of increased mortality attributable to Ranexa based on two year survival rates of ROLE participants compared with published outcomes of similar cohorts used as a reference population.

Because ROLE was an open label study, and not a placebo controlled clinical trial with a comparator group, it does not allow for a rigorous analysis for mortality and it is difficult to fully characterize the implications of the deaths reported in the study.

The ROLE program evaluated 746 patients with chronic angina who chose to receive Ranexa(R) following their participation in the phase 3 Monotherapy Assessment of Ranolazine In Stable Angina (MARISA) or the phase 3 Combination Assessment of Ranolazine In Stable Angina (CARISA) clinical studies with Ranexa. More than 85 percent of eligible MARISA patients and more than 80 percent of eligible CARISA patients chose to receive Ranexa in the ROLE program.

The mean duration of follow-up was 2.82 years and more than 75 percent of ROLE patients completed at least two years of Ranexa therapy. Two years after initial dosing, 9.7 percent of patients had discontinued Ranexa due to adverse events.

No treatment discontinuations occurred due to QT prolongation and no cases of torsades de pointes were reported. The most commonly reported adverse events, other than angina, were dizziness (11.8 percent) and constipation (10.9 percent).

"The high rate of patients choosing
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
2. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
3. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
4. The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke
5. MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases
6. Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
7. Calando Pharmaceuticals Publishes Study Showing Anti-Cancer Effect with Lead RNAi Candidate
8. Medical Journal Publishes First Large-Scale Survey Revealing Experiences of IPF Patients
9. Arrowhead Subsidiary, Calando Pharmaceuticals Publishes Study on Targeted, Systemic Delivery of siRNA
10. Calando Pharmaceuticals Publishes the First Non-Human Primate Study on Targeted, Systemic Delivery of siRNA in National Academy of Sciences Journal
11. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
Post Your Comments:
(Date:7/24/2014)... , July 24, 2014 LSI Medience ... an Agreement with Kineticos, a Raleigh-Durham, ... Kineticos will support LSI Medience in identifying opportunities ... to demonstrate utility in clinical trials. ... utility in diagnosis of sepsis, prognosis of septic ...
(Date:7/24/2014)...  The American Association for Homecare (AAHomecare) yesterday ... help address audit issues in the HME industry ... the information technology lead in shaping its HME ... billing and business management solutions for nearly 3,000 ... support this important initiative on behalf of all ...
(Date:7/24/2014)... , July 24, 2014 Decision Resources Group ... the EU5 countries ( France , ... Spain and the ... of the first once-daily long-acting beta2 agonist/inhaled corticosteroid (LABA/ICS) ... uptake of Relvar as a first-line LABA/ICS FDC in ...
Breaking Medicine Technology:LSI Medience Corporation and Kineticos Sign Agreement Related to the Presepsin Biomarker in Sepsis Management and Treatment 2Brightree Joins AAHomecare as Corporate Partner and IT Lead on HME Audit Key 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 2Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma 3
... Calif., Nov. 17 Poniard Pharmaceuticals, Inc. (Nasdaq: ... randomized, controlled Phase 2 trial of picoplatin in patients ... indicated that picoplatin, given once every four weeks in ... has comparable efficacy to oxaliplatin, given in combination with ...
... , LAKE ZURICH, Ill., Nov. 17 ... improving blood collection, separation, safety and availability, announced today ... the Verax Platelet PGD® test as a quality control ... platelets prior to transfusion. Fenwal is the exclusive ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 3Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 4Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 5FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 2FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 3FDA Clears the First Rapid Test to Detect Bacteria in Pooled Platelets 4
(Date:7/24/2014)... BUFFALO, N.Y. Primary care treatment of overweight and ... and child compared to when only the child is ... Pediatrics and conducted at the University at Buffalo ... in this study were overweight or obese and had ... was overweight or obese, according to body mass index ...
(Date:7/24/2014)... caffeine may worsen the hot flashes and night sweats ... through menopause, new survey data suggests. "While these ... intake may be useful for those postmenopausal women who ... Dr. Stephanie Faubion, director of the Women,s Health Clinic ... caffeine -- a stimulant found in coffee and colas ...
(Date:7/24/2014)... 24, 2014 A new study led by the ... interplay among bacteria, viruses and the immune system during ... their potential to infect others based on ... amounts of virus in their semen despite having low ... different levels of the virus can be found in ...
(Date:7/24/2014)... July 24, 2014 Memantine was initially developed ... marketed in Germany under the brand name Akatinol; it was ... as Ebixa and in the USA to Forest Labs as ... million in 2013. In the US, Forest reported Namenda sales ... expiry in Canada, Australia and the European region has increased ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Members of the ... Wolnerman, RPh, CCIM, Senior Associate of Sales at OutcomesMTM, as ... appointed him to the Board and that his peers chose ... want to provide the best I can for the citizens ... am uniquely positioned to provide a special insight to concerns ...
Breaking Medicine News(10 mins):Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Is Coffee Aggravating Your Hot Flashes? 2Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 2Health News:Memantine Discussed in New Comprehensive Patent Search Report by Ark Patent Intelligence Published at MarketPublishers.com 3Health News:Wolnerman Re-elected as Chairperson of Iowa State Board of Health 2
... research leads to groundbreaking conclusions. Valuable research data all ... unexposed to the light of day, and unused by ... dark data, is now being set free with the ... Research Notes, a new open access journal, is publishing ...
... NEW YORK, Feb. 26 On February 25, ... DGMS.PK) (http://www.digimedical.com ),updated the investment community in ... in the interview include an overview of the,company ... opportunity,and upcoming milestones for which investors should watch., ...
... of UPMC has been selected to join an effort ... to collect and study information necessary to understand the ... called primary sclerosing cholangitis (PSC). , The Studies of ... effort initiated, funded and organized by The Musette and ...
... R.I. Adults and teens that underwent surgery as infants ... face to appear uneven still have a degree of facial ... Hasbro Childrens Hospital surgeon. , The study, published in the ... coronal synostosis, a type of craniosynostosis, in which the bones ...
... "It is not clear that the,benefits of ... or other effects such as dental fluorosis," according ... Fluoride chemicals are added to 2/3 of U.S. ... is found in dental products,supplements and virtually all ...
... Court, WILMINGTON, Del., Feb. 26 The following,statement ... W.Va., zinc smelter,class action lawsuit late Monday. The statement ... Mobley., "We are extremely disappointed by the rulings ... the recent rulings and the earlier,jury verdicts. We believe ...
Cached Medicine News:Health News:Shining light on science's 'dark data:' New venture ensures a fuller scientific record 2Health News:WallSt.net (www.wallst.net) Updates Investment Community Through All-New Interview With digiMedical Solutions 2Health News:Children's Hospital 1 of 10 pediatric hospitals in US selected to study liver disease in kids 2Health News:Facial asymmetry persists despite surgery to correct congenital deformity 2Health News:Fluoride May Damage the Brain, New Report Says 2Health News:DuPont Responds to Spelter, W.Va. Lawsuit Rulings 2
... The THERMOstar is a high performance temperature ... microplates. Temperature, shaking speed and incubation time ... the status parameters are displayed on the ... above and below the microplates provide uniform ...
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -...
Minimal M9 Broth...
An agent used for making solid microbiological media....
Medicine Products: